Novartis (NVS) Debt to Equity (2006 - 2026)
Novartis (NVS) debt to equity from Mar 31, 2006 to Mar 31, 2026. The current Novartis (NVS) debt to equity is 122.03%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Debt to Equity
Annual Debt to Equity change of Novartis (NVS)
| Year | Debt to Equity | Change |
|---|---|---|
| 2025 | 80.28% | +13.12% |
| 2024 | 70.97% | +25.69% |
| 2023 | 56.46% | +20.05% |
| 2022 | 47.03% | +2.56% |
| 2021 | 45.86% | -31.44% |
| 2020 | 66.88% | +27.29% |
| 2019 | 52.54% | +28.72% |
| 2018 | 40.82% | +6.51% |
| 2017 | 38.33% | +20.49% |
| 2016 | 31.81% | +11.74% |
| 2015 | 28.46% | -1.31% |
| 2014 | 28.84% | +19.01% |
| 2013 | 24.24% | -15.11% |
| 2012 | 28.55% | -6.93% |
| 2011 | 30.68% | -15.50% |
| 2010 | 36.30% | +49.80% |
| 2009 | 24.24% | +73.24% |
| 2008 | 13.99% | +23.12% |
| 2007 | 11.36% | -35.27% |
| 2006 | 17.55% | N/A |
Comparison Novartis (NVS) debt to equity with competitors
Novartis (NVS) debt to equity is 122.03%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| SNY | Sanofi | 27.50% | -77.47% |
| BIIB | Biogen Inc | 33.72% | -72.37% |
| JNJ | Johnson & Johnson | 67.73% | -44.50% |
| PFE | Pfizer Inc | 71.50% | -41.41% |
| AZN | Astrazeneca plc | 71.66% | -41.28% |
| GILD | Gilead Sciences Inc | 94.30% | -22.73% |
| GSK | GSK Plc | 106.74% | -12.53% |
| MRK | Merck & Co Inc | 107.06% | -12.27% |
| LLY | Lilly(Eli) & Company | 139.02% | +13.91% |
| MDCX | MDCorp | 176.75% | +44.83% |
| MDCXW | Medicus Pharma Ltd warrant | 176.75% | +44.83% |
| GRFS | Grifols SA | 177.15% | +45.17% |
| BMY | Bristol-Myers Squibb Company | 219.95% | +80.24% |
| AMGN | AMGEN Inc | 623.75% | +411.13% |
| OGN | Organon & Company | 948.95% | +677.61% |